This Article Full Text Full Text (PDF) All Versions of this Article: 120/18/1745    most recent CIRCULATIONAHA.109.900415v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Google Scholar Articles by MacRae, C. A. PubMed PubMed Citation Articles by MacRae, C. A. Related Collections Clinical genetics Arrythmias-basic studies Arrhythmias, clinical electrophysiology, drugs Related Articles

(Circulation. 2009;120:1745-1748.)
© 2009 American Heart Association, Inc.

Editorial

Closer Look at Genetic Testing in Long-QT Syndrome

Will DNA Diagnostics Ever Be Enough?

Calum A. MacRae, MD, PhD

From Brigham and Women’s Hospital and Harvard Medical School, Boston, Mass.

Correspondence to Calum A. MacRae, MD, PhD, Cardiovascular Division, Brigham and Women’s Hospital, Thorn 11, 75 Francis St, Boston, MA 02115. E-mail cmacrae@partners.org

Key Words: Editorials • genetics • long-QT syndrome • molecular diagnostic testing

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
Increasingly affordable sequencing has led to an explosion of DNA diagnostics and has fueled the hope for a genetic revolution in medicine. The popular vision is of definitive prediction of lifetime risk for a broad range of conditions from the primary analysis of each individual’s genomic sequence.^1,2 The resultant panel of sequence variants will define the specific traits to which an individual is susceptible, triggering the institution of preventive measures or targeted therapies. Efficacy and safety will be largely assured for each of the chosen interventions. However, with the potential exception of pharmacogenetic studies in which the molecular targets are known, robust genotype-phenotype correlations are remarkably sparse and, in most instances, simply inadequate for rigorous risk prediction.³ Although genetics has transformed our understanding of the biology of disease, on closer examination it is not immediately evident when the "genomic revolution" will be realized as currently conceived for many cardiovascular conditions.^3,4

Articles see pp 1752 and 1761

	Current Genetic Testing in Familial Long-QT Syndrome

 
Nothing tests the tools of clinical risk prediction quite like sudden death.⁵ The difficulties encountered in the clinical application of genetic data, even in inherited conditions such as the long-QT syndrome (LQTS), in which the transmitted risk of sudden death is several hundred-fold greater than that in the general population, highlight some of the hurdles that must be overcome if DNA diagnosis is ever to transform cardiovascular medicine. Genetic testing for LQTS has been commercially available for several years, but a critical analysis of the clinical utility of test results reveals a rather mixed . . . [Full Text of this Article]

Related Articles:

Genetic Testing for Long-QT Syndrome: Distinguishing Pathogenic Mutations From Benign Variants

Suraj Kapa, David J. Tester, Benjamin A. Salisbury, Carole Harris-Kerr, Manish S. Pungliya, Marielle Alders, Arthur A.M. Wilde, and Michael J. Ackerman
Circulation 2009 120: 1752-1760. [Abstract] [Full Text]

Prevalence of the Congenital Long-QT Syndrome

Peter J. Schwartz, Marco Stramba-Badiale, Lia Crotti, Matteo Pedrazzini, Alessandra Besana, Giuliano Bosi, Fulvio Gabbarini, Karine Goulene, Roberto Insolia, Savina Mannarino, Fabio Mosca, Luigi Nespoli, Alessandro Rimini, Enrico Rosati, Patrizia Salice, and Carla Spazzolini
Circulation 2009 120: 1761-1767. [Abstract] [Full Text]